Xtl Biopharmaceuticals (XTLB) Other financing activities (2011 - 2015)
Xtl Biopharmaceuticals (XTLB) posted quarterly Other financing activities of -$12000.0 for Q2 2015, down 101.71% year-on-year from $703000.0 in Q2 2014, and down 102.33% on a QoQ basis from $515000.0 in Q4 2014.
Xtl Biopharmaceuticals (XTLB) Other financing activities (2011 - 2015) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Other financing activities for 5 consecutive years, with -$12000.0 the latest figure, recorded in Q2 2015.
- Quarterly Other financing activities fell 101.71% year-over-year to -$12000.0 in Q2 2015, while the trailing twelve-month figure through Jun 2015 was $1.4 million (up 182.89% YoY) and the FY2015 annual result came in at $20000.0, down 98.36% from the prior year.
- Other financing activities fell to -$12000.0 in Q2 2015 per XTLB's latest filing, from $515000.0 in the prior quarter.
- Over the last five years, Other financing activities for XTLB reached as high as $1.1 million in Q3 2013 and fell as low as -$1.9 million in Q1 2011.
- A 5-year average of -$64764.7 and a median of $25000.0 in 2011 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2012 — Other financing activities slumped 6496.0% — and 2014, when it jumped 70400.0%.
- Year by year, Other financing activities stood at -$977000.0 in 2011, then soared by 203.17% to $1.0 million in 2012, then tumbled by 226.39% to -$1.3 million in 2013, then soared by 140.42% to $515000.0 in 2014, then sank by 102.33% to -$12000.0 in 2015.
- According to Business Quant data, Other financing activities over the past three periods registered -$12000.0, $515000.0, and $166000.0 for Q2 2015, Q4 2014, and Q3 2014 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | -12,000.00 |
| Jun 30, 2015 | -12,000.00 |
| Dec 31, 2014 | 515,000.00 |
| Dec 31, 2014 | 515,000.00 |
| Sep 30, 2014 | 166,000.00 |
| Sep 30, 2014 | 166,000.00 |
| Jun 30, 2014 | 703,000.00 |
| Jun 30, 2014 | 703,000.00 |
| Mar 31, 2014 | -2,000.00 |
| Mar 31, 2014 | -2,000.00 |
| Dec 31, 2013 | -1.27 Mn |
| Dec 31, 2013 | -1.27 Mn |
| Sep 30, 2013 | 1.06 Mn |
| Sep 30, 2013 | 1.06 Mn |
| Jun 30, 2013 | -1,000.00 |
| Jun 30, 2013 | -1,000.00 |
| Mar 31, 2013 | 583,000.00 |
| Mar 31, 2013 | 583,000.00 |
| Dec 31, 2012 | 1.01 Mn |
| Dec 31, 2012 | 1.01 Mn |